| Date | Title | Download |
|---|---|---|
| 11.4.08 | Vion Updates Conference Call Information |  |
| 11.3.08 | Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday November 6 at 8:30 a.m. | |
| 9.22.08 | Vion Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine® in Combination with Induction Therapy in Poor Prognosis AML Patients | |
| 8.19.08 | Vion Enters into Agreement with HOVON to Conduct a Phase III Clinical Trial of Cloretazine® in combination with Frontline AML and MDS Therapy | |
| 8.14.08 | Vion is Delisted from Nasdaq Stock Market | |
| 8.4.08 | Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday August 7 at 8:30 a.m. | |
| 6.13.08 | Vion Announces Presentation of Data of Cloretazine® (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting | |
| 6.2.08 | Vion Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Acute Myelogenous Leukemia at the ASCO® Annual Meeting |
|
| 6.2.08 | Vion Announces Presentation of Data from Phase III Trial of Cloretazine® (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO® Annual Meeting | |
| 5.30.08 | Vion To Present Clinical Data on Cloretazine® (VNP40101M) at the ASCO® Annual Meeting |
|
| 5.8.08 | Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Cytarabine | |
| 5.8.08 | Vion To Appeal Nasdaq Delisting | |
| 5.6.08 | Vion to Host Conference Call To Discuss 2008 First Quarter Financial Results | |
| 5.5.08 | Vion Reports 2008 First Quarter Results | |
| 4.15.08 | Vion Files Plan With Nasdaq | |
| 3.26.08 | Vion Receives Nasdaq Notice | |
| 3.17.08 | Vion Reports 2007 Fourth Quarter and Year-End Results | |
| 3.14.08 | Vion to Host Conference Call To Discuss 2007 Fourth Quarter and Year-End Financial Results | |
| 3.7.08 | Vion Regains NASDAQ Listing Compliance | |
| 2.20.08 | Vion to Implement a One-for-Ten Reverse Stock Split | |
| 2.15.08 | Vion Pays Interest on 7.75% Convertible Senior Notes | |
| 2.13.08 | Vion Holds Special Meeting of Stockholders | |
| 2.4.08 | Vion Adds William Hahne, M.D. to Senior Management Team | |
| 1.8.08 | Vion Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine® (VNP40101M) and Cytarabine in Relapsed AML | |